Title: N-acetylcysteine modulates markers of oxidation, inflammation and infection in tuberculosis: Supplemental appendix

Short title: NAC biomarkers in TB supplement

Authors: Daniel Adon Mapamba1,2, Issa Sabi1, Julieth Lalashowi1, Elingarami Sauli2, Joram Buza2, Willyhelmina Olomi1, Bariki Mtafya1, Michael Kibona1, Abhishek Bakhuli3, Andrea Rachow3,4,5, Kavindhran Velen7, Michael Hoelscher3,4,5,6, Nyanda E Ntinginya2, Salome Charalambous7,8, Gavin Churchyard7,9,10, Robert S. Wallis7,8,9, and the TB SEQUEL consortium

Affiliations: 1 National Institute for Medical Research-Mbeya Medical Research Center, Mbeya, Tanzania; 2 The Nelson Mandela African Institution of Science and Technology, Arusha, Tanzania; 3 Division of Infectious Diseases and Tropical Medicine, Medical Centre of the University of Munich (LMU), Munich, Germany; 4 German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany; 5 Unit Global Health, Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Neuherberg, Germany; 6 Fraunhofer Institute for Translational Medicine and Pharmacology ITMP; Immunology, Infection and Pandemic Research, Munich, Germany; 7 The Aurum Institute, Johannesburg, South Africa; 8 Case Western Reserve University, Cleveland USA; 9 Department of Medicine, Vanderbilt University, Nashville USA; 10 School of Public Health, University of Witwatersrand, Johannesburg, South Africa

Correspondence: dmapamba@nimr-mmrc.org

Funding: German Ministry for Education and Research (BMBF) grant 01KA1613 for TB SEQUEL

**Table of contents**

Table s1. Participant demographic and baseline data 3

Figure s1. Screening and eligibility 4

|  |  |  |
| --- | --- | --- |
| **Parameter** | **Patients with tuberculosis** | **Healthy**  |
| **Control arm**  | **NAC arm**  | **Volunteers** |
|  |  | *n=70* | *n=69* | *n=82* |
| Sex | male | 54 (77%) | 50 (72%) | 43 (53.4%) |
| Female | 16 (23%) | 19 (28%) | 39 (47.6%) |
| Age median (IQR) | years  | 35 (29, 40) | 34 (29, 41) | 30 (25,38) |
| BMI mean (SD) | kg/m2  | 19.71 (3.46) | 19.69 (2.83) | - |
| HIV-1 status | positive  | 23 (32.9%) | 19 (27.5%) | - |
| Negative | 47 (67.1%) | 50 (72.5%) | - |
| CD4+ T cells (if HIV+) | <200/ul  | 3 (13.0%) | 3 (15.8%) | - |
| ≥200/ul | 20 (87.0%) | 16 (84.2%) | - |
| Radiographic extent of disease | far advanced  | 33 (47%) | 32 (46%) | - |
| moderate | 37 (53%) | 37 (54%) | - |
| Spirometry  | FEV1% | 60.4 (18.5) | 62.3 (14.7) | - |
| FVC% | 65.6 (17.4) | 68.3 (12.9) | - |
| Performed | 44 (62.9%) | 41 (59.4%) |  |
| ND/NS | 26 (37.1%) | 28 (40.6%) | - |
| Sputum AFB smear n (%) | Negative  | 1 (1.4%) | 4 (5.8%) | - |
| Scanty | 2 (2.9%) | 2 (2.9%) | - |
| 1+ | 2 (2.9%) | 4 (5.8%) | - |
| 2+ | 4 (5.7%) | 6 (8.7%) | - |
| 3+ | 61 (87%) | 53 (77%) | - |
| MGIT culture | Positive for MTB  | 70 (100%) | 69 (100%) | - |
|  | TTP days median (IQR) | 3.60 (2.96, 4.17) | 3.67 (2.99, 5.15) | - |
| Glutathione  | Total uM/l | 653.3±145.7 | 643.1±177.6 | 1345.9±480.8 |
| CRP  | mg/dl | 97.04±56.35 | 85.55±51.73 |  |
| Hemoglobin  | g/dl | 12.03±2.07 | 12.38±2.03 |  |
| TNF  | log pg/mL | 3.09±0.36 | 2.98±0.33 | - |
| IL-10  | log pg/mL | 2.31±0.44 | 2.31±0.57 | - |

Table s1. Participant demographic and baseline data of the modified intention to treat (mITT) patient population and healthy controls. Values are mean±SD unless otherwise indicated.



Figure s1. Screening and eligibility. Ct=Xpert cycle threshold. ITT=intention to treat. PP=per protocol. MDR=multidrug resistant.